comparemela.com

Latest Breaking News On - Nektar therapeutics - Page 8 : comparemela.com

Pfizer's migraine market chief joins Apnimed—Chutes & Ladders

Pfizer's migraine market chief joins Apnimed—Chutes & Ladders
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

San-diego
California
United-states
France
Ireland
Connecticut
French
Paul-willems
Madam-townsend
Samuel-collins
Mary-lynne-hedley
Kirk-shepard

Nektar Therapeutics (NASDAQ:NKTR) Expected to Earn FY2023 Earnings of ($0.85) Per Share

Nektar Therapeutics (NASDAQ:NKTR – Free Report) – Equities research analysts at Zacks Research lowered their FY2023 earnings per share estimates for shares of Nektar Therapeutics in a research note issued to investors on Tuesday, January 23rd. Zacks Research analyst K. Das now expects that the biopharmaceutical company will post earnings per share of ($0.85) for […]

Monaco
United-states
Acadian-asset-management
Nektar-therapeutics-company-profile
Blackrock-inc
Jpmorgan-chase-co
Zacks-research
Nektar-therapeutics
Free-report
Nektar-therapeutic
Get-free-report

DiaMedica Therapeutics Inc. (DMAC) Appoints Lorianne Masuoka as Chief Medical Officer

DiaMedica Therapeutics Inc. (DMAC) Appoints Lorianne Masuoka as Chief Medical Officer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states
California
American
Rick-pauls
Marinus-pharmaceuticals
Amgen
Pfenex-inc
Diamedica-therapeutics-inc
Nektar-therapeutics
Nasdaq
Novartis
University-of-california

Nektar Therapeutics (NASDAQ:NKTR) Receives $3.00 Consensus PT from Brokerages

Nektar Therapeutics (NASDAQ:NKTR) Receives $3.00 Consensus PT from Brokerages
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United-states
Nektar-therapeutics-company-profile
Jpmorgan-chase-co
Nektar-therapeutics
Tower-research-capital
Life-insurance-co
Syntax-advisors
Get-free-report
Marketbeat-ratings
Therapeutics-stock-down
Advocates-investment-management

Nektar Therapeutics (NASDAQ:NKTR) Receives $3.00 Consensus Price Target from Analysts

Nektar Therapeutics (NASDAQ:NKTR) Receives $3.00 Consensus Price Target from Analysts
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United-states
Syntax-advisors
Jpmorgan-chase-co
Nektar-therapeutics-company-profile
Nektar-therapeutics
Tower-research-capital
Life-insurance-co
Get-free-report
Advocates-investment-management
Research-capital
Get-free

vimarsana © 2020. All Rights Reserved.